Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Adagene Inc. before investing.

In this article, we go over a few key elements for understanding Adagene Inc.’s stock price such as:

• Adagene Inc.’s current stock price and volume
• Why Adagene Inc.’s stock price changed recently
• Upgrades and downgrades for ADAG from analysts
• ADAG’s stock price momentum as measured by its relative strength

About Adagene Inc. (ADAG)

Before we jump into Adagene Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Want to learn more about Adagene Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Adagene Inc..

Adagene Inc.’s Stock Price as of Market Close

As of November 28, 2025, 12:59 PM, CST, Adagene Inc.’s stock price was $2.010.

Adagene Inc. is down 5.19% from its previous closing price of $2.120.

During the last market session, Adagene Inc.’s stock traded between $2.000 and $2.140. Currently, there are approximately 47.11 million shares outstanding for Adagene Inc..

Adagene Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Adagene Inc. Stock Price History

Adagene Inc.’s (ADAG) price is currently up 12.92% so far this month.

During the month of November, Adagene Inc.’s stock price has reached a high of $2.140 and a low of $1.300.

Over the last year, Adagene Inc. has hit prices as high as $3.160 and as low as $1.300. Year to date, Adagene Inc.’s stock is up 1.01%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Adagene Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were analysts who downgraded Adagene Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Adagene Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Adagene Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Adagene Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Adagene Inc. (ADAG) by visiting AAII Stock Evaluator.

Relative Price Strength of Adagene Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Adagene Inc. has a weighted four-quarter relative price strength of -6.61%, which translates to a Momentum Score of 36 and is considered to be Weak.

Want to learn more about how Adagene Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Adagene Inc. Stock Price: Bottom Line

As of November 28, 2025, Adagene Inc.’s stock price is $2.010, which is down 5.19% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Adagene Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.